In this study, we revealed that cancer cell‐intrinsic SMYD3 impaired the response of ccRCC to a PD‐1 inhibitor by affecting the infiltration of immune cells in the tumor microenvironment shaped by immunosuppression. Here, SMYD3 is linked to nonpapillary renal cell carcinoma.